Literature DB >> 17551084

Different CTNNB1 mutations as molecular genetic proof for the independent origin of four Wilms tumours in a patient with a novel germ line WT1 mutation.

Constanze Uschkereit, Noelia Perez, Carmen de Torres, Maike Küff, Jaume Mora, Brigitte Royer-Pokora.   

Abstract

We describe a patient with a novel WT1 pS50X germ line mutation, who developed bilateral Wilms tumours, both with stromal-type histology. Both tumours showed loss of the wild type WT1 allele (loss of heterozygosity (LOH)) and a tumour specific mutation in catenin beta1 (CTNNB1), S45P in the left and Delta45S in the right tumour. Molecular analysis of microdissected cells from the left tumour revealed the same S45P CTNNB1 mutation in blastema, tubuli, stroma and muscle, and a different CTNNB1 mutation (T41A) in stromal cells isolated from another area of the same slide. Microdissection of two areas of muscle cells from the right tumour revealed the same Delta45S mutation and no CTNNB1 mutation nor LOH of WT1 in normal kidney cells. One year later, the patient developed a new set of bilateral tumours. Both tumours showed LOH of the wild type WT1 allele, but different CTNNB1 mutations as in the first tumours: S45C on the right and S45F on the left side, demonstrating that these developed independently and are not relapses. This case demonstrates the high risk for the development of Wilms tumours in patients with germ line truncation mutations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17551084      PMCID: PMC2740887          DOI: 10.1136/jmg.2006.047530

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  11 in total

1.  Correlation between a specific Wilms tumour suppressor gene (WT1) mutation and the histological findings in Wilms tumour (WT).

Authors:  R Shibata; A Hashiguchi; J Sakamoto; T Yamada; A Umezawa; J Hata
Journal:  J Med Genet       Date:  2002-12       Impact factor: 6.318

2.  Frequent association of beta-catenin and WT1 mutations in Wilms tumors.

Authors:  S Maiti; R Alam; C I Amos; V Huff
Journal:  Cancer Res       Date:  2000-11-15       Impact factor: 12.701

3.  Correlation of germ-line mutations and two-hit inactivation of the WT1 gene with Wilms tumors of stromal-predominant histology.

Authors:  V Schumacher; S Schneider; A Figge; G Wildhardt; D Harms; D Schmidt; A Weirich; R Ludwig; B Royer-Pokora
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

Review 4.  A WT1 exon 1 mutation in a child diagnosed with Denys-Drash syndrome.

Authors:  Suzanne Little; Sandra Hanks; Linda King-Underwood; Sue Picton; Catherine Cullinane; Elizabeth Rapley; Nazneen Rahman; Kathy Pritchard-Jones
Journal:  Pediatr Nephrol       Date:  2004-10-21       Impact factor: 3.714

Review 5.  A clinical overview of WT1 gene mutations.

Authors:  M Little; C Wells
Journal:  Hum Mutat       Date:  1997       Impact factor: 4.878

6.  Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors.

Authors:  R Koesters; R Ridder; A Kopp-Schneider; D Betts; V Adams; F Niggli; J Briner; M von Knebel Doeberitz
Journal:  Cancer Res       Date:  1999-08-15       Impact factor: 12.701

7.  Codon 45 of the beta-catenin gene, a specific mutational target site of Wilms' tumor.

Authors:  Takeshi Kusafuka; Jiangyong Miao; Seika Kuroda; Yoko Udatsu; Akihiro Yoneda
Journal:  Int J Mol Med       Date:  2002-10       Impact factor: 4.101

8.  CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.

Authors:  Chi-Ming Li; Connie E Kim; Adam A Margolin; Meirong Guo; Jimmy Zhu; Jacqueline M Mason; Terrence W Hensle; Vundavalli V V S Murty; Paul E Grundy; Eric R Fearon; Vivette D'Agati; Jonathan D Licht; Benjamin Tycko
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

9.  Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.

Authors:  Ryuji Fukuzawa; Rosemary W Heathcott; Makoto Sano; Ian M Morison; Kankatsu Yun; Anthony E Reeve
Journal:  Pediatr Dev Pathol       Date:  2004-03-04

10.  Twenty-four new cases of WT1 germline mutations and review of the literature: genotype/phenotype correlations for Wilms tumor development.

Authors:  Brigitte Royer-Pokora; Manfred Beier; Markus Henzler; Rita Alam; Valérie Schumacher; Angela Weirich; Vicki Huff
Journal:  Am J Med Genet A       Date:  2004-06-15       Impact factor: 2.802

View more
  9 in total

Review 1.  Wilms tumor--a renal stem cell malignancy?

Authors:  Naomi Pode-Shakked; Benjamin Dekel
Journal:  Pediatr Nephrol       Date:  2011-04-16       Impact factor: 3.714

2.  An integrated genome screen identifies the Wnt signaling pathway as a major target of WT1.

Authors:  Marianne K-H Kim; Thomas J McGarry; Pilib O Broin; Jared M Flatow; Aaron A-J Golden; Jonathan D Licht
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-22       Impact factor: 11.205

Review 3.  Genetics of pediatric renal tumors.

Authors:  Brigitte Royer-Pokora
Journal:  Pediatr Nephrol       Date:  2012-03-30       Impact factor: 3.714

4.  Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study.

Authors:  Samantha Gadd; Vicki Huff; Chiang-Ching Huang; E Cristy Ruteshouser; Jeffrey S Dome; Paul E Grundy; Norman Breslow; Lawrence Jennings; Daniel M Green; J Bruce Beckwith; Elizabeth J Perlman
Journal:  Neoplasia       Date:  2012-08       Impact factor: 5.715

Review 5.  Is Wilms tumor a candidate neoplasia for treatment with WNT/β-catenin pathway modulators?--A report from the renal tumors biology-driven drug development workshop.

Authors:  Daniela Perotti; Peter Hohenstein; Italia Bongarzone; Mariana Maschietto; Mark Weeks; Paolo Radice; Kathy Pritchard-Jones
Journal:  Mol Cancer Ther       Date:  2013-11-20       Impact factor: 6.261

Review 6.  Bilateral Wilms tumour: a review of clinical and molecular features.

Authors:  Jocelyn Charlton; Sabine Irtan; Christophe Bergeron; Kathy Pritchard-Jones
Journal:  Expert Rev Mol Med       Date:  2017-07-18       Impact factor: 5.600

7.  Stromal β-catenin activation impacts nephron progenitor differentiation in the developing kidney and may contribute to Wilms tumor.

Authors:  Keri A Drake; Christopher P Chaney; Amrita Das; Priti Roy; Callie S Kwartler; Dinesh Rakheja; Thomas J Carroll
Journal:  Development       Date:  2020-07-31       Impact factor: 6.868

8.  Establishment of a Conditionally Immortalized Wilms Tumor Cell Line with a Homozygous WT1 Deletion within a Heterozygous 11p13 Deletion and UPD Limited to 11p15.

Authors:  Artur Brandt; Katharina Löhers; Manfred Beier; Barbara Leube; Carmen de Torres; Jaume Mora; Parineeta Arora; Parmjit S Jat; Brigitte Royer-Pokora
Journal:  PLoS One       Date:  2016-05-23       Impact factor: 3.240

9.  Chemotherapy and terminal skeletal muscle differentiation in WT1-mutant Wilms tumors.

Authors:  Brigitte Royer-Pokora; Manfred Beier; Artur Brandt; Constanze Duhme; Maike Busch; Carmen de Torres; Hans-Dieter Royer; Jaume Mora
Journal:  Cancer Med       Date:  2018-03-15       Impact factor: 4.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.